Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source updated2026-05-18Last update listed in the registry record
Version history
Changes to this trial
Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
· 2 fields changed
Primary outcomes · main study measures
Text edit · unverified significance
− Previous value
measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis; measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)
+ Updated value
measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis; measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis); measure: Incidence of Treatment Emergent Adverse Events
The saved outcome text may be shortened. Check the source for full wording.
Trial